

## 1H FY21 RESULTS PRESENTATION

CLEANSPACE HOLDINGS LIMITED (ASX:CSX)



CleanSpace designs and manufactures innovative respiratory protection solutions for healthcare & industrial employers globally

We understand the importance of best-in-class personal protective equipment that not only performs, but allows the wearer to work comfortably and interact naturally in their work environment. Our products are designed for maximum compliance and comfort in the industrial and healthcare setting.

FEBRUARY 2021

# IMPORTANT NOTICE & DISCLAIMER

## ACCEPTANCE

This presentation has been prepared by CleanSpace Holdings Limited (ACN 150 214 636) (CleanSpace).

By accepting, accessing or reviewing this presentation, you acknowledge and agree to the terms set out in this Important Notice and Disclaimer.

## SUMMARY OF INFORMATION

This presentation has been provided to you solely to convey information about CleanSpace and its related entities, and their activities, for the half-year period ended 31 December 2020. The information in this presentation is general in nature and does not purport to be complete, nor does it contain all the information which a prospective investor may require in evaluating a possible investment in CleanSpace. It has been prepared by CleanSpace with due care, but other than as required by law, no representation or warranty, express or implied, is provided in relation to the accuracy, fairness or completeness of the information. Statements in this presentation are made only as of the date of this presentation, unless otherwise stated, and the information in this presentation remains subject to change without notice.

None of CleanSpace, its representatives or advisers is responsible for updating, or undertakes to update, this presentation. Items depicted in photographs and diagrams are not assets of CleanSpace, unless stated.

This presentation should be read in conjunction with CleanSpace's Half-Year Financial Report for the period ended 31 December 2020 as well as other periodic and continuous disclosure information lodged with the ASX, which are available at [www.asx.com.au](http://www.asx.com.au) and the CleanSpace's Investor page accessible via <https://cleanspacetechnology.com/investor/>.

## NOT FINANCIAL PRODUCT ADVICE OR OFFER

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Corporations Act or other disclosure document under Australian law or the law of any other jurisdiction. It is not, and should not be considered as, an offer, invitation, solicitation, advice or recommendation to buy or sell or to refrain from buying or selling any securities or other investment product or to enter into any other transaction in any jurisdiction. It has been prepared without accounting for any person's individual objectives, financial or tax situation or any particular needs. Readers should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs, make their own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of CleanSpace and the impact that different future outcomes may have on CleanSpace, and seek legal and taxation advice appropriate for their jurisdiction.

## FINANCIAL DATA

Investors should note that this presentation contains pro forma historical financial information. The pro forma financial information, and the historical information, provided in this presentation is for illustrative purposes only and is not represented as being indicative of CleanSpace's views on its future financial condition and/or performance.

CleanSpace's financial results are reported under International Financial Reporting Standards (IFRS). This release includes certain non-IFRS measures including EBITDA and Free Cash Flow. These measures are presented to enable understanding of the underlying performance of the Company without the impact of non-trading items and foreign currency impacts. Non-IFRS measures have not been subject to audit or review.

All currency figures in this presentation are in Australian dollars (\$) or (A\$) unless stated otherwise.

## EFFECT OF ROUNDING

A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation.

## PAST PERFORMANCE

Past performance of CleanSpace, including past share price performance, cannot, and should not, be relied upon as an indicator of (and provides no guidance as to) future CleanSpace performance. Nothing contained in this presentation nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

Future performance and forward-looking statements

This presentation may contain forward-looking statements with respect to the operations and businesses of the Company. The assumptions underlying these forward-looking statements involve circumstances and events that have not yet taken place, and which are subject to uncertainty and contingencies outside the Company's control. Readers are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to publicly release the result of any revisions to forward-looking statements in this presentation or to otherwise update forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this presentation, except as required by law.

No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement or estimate by any person (including CleanSpace). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based.

## AUTHORISATION

This presentation has been authorised for lodgement to the ASX by the CleanSpace Board of Directors.

# CLEANSPACE PRESENTERS



## Alex Birrell

CHIEF EXECUTIVE OFFICER

- 20+ years in senior management roles in the healthcare and technology sectors
- Previous roles at PricewaterhouseCoopers in healthcare advisory practice and financial services (Technology) and Royal Prince Alfred Hospital
- Dr Birrell has a PhD, MBA and Bachelor of Veterinary Medicine
- With the Company since 2010, CEO since 2014



## Elizabeth Harvey

CHIEF FINANCIAL OFFICER

- 20+ years' experience in financial operations in financial control, business performance and analysis, risk management and compliance
- Prior to joining CleanSpace, Ms Harvey worked at Macquarie Group for over 12 years as a finance director, and also Credit Suisse in London and KPMG (Sydney and London)
- Ms Harvey is a chartered accountant (CA) and has a Bachelor of Commerce and MBA
- Joined CleanSpace as its Chief Financial Officer and Company Secretary in 2017

# 1H FY21 FINANCIAL HIGHLIGHTS

## REVENUE

**\$39.7M**

▲ **5x** | 1H FY20 \$7.3M

## GROSS MARGIN

**78%**

▲ **10%** | 1H FY20 68%

## OPERATING EXPENSES<sup>1</sup>

**28%**

OF TOTAL SALES

## EBITDA<sup>1</sup>

**\$20.1M**

## CONSUMABLE / ACCESSORIES SALES

**49%**

OF TOTAL SALES

## HEALTHCARE SALES

**78%**

OF TOTAL SALES

1. Pro Forma Income Statement

# 1H FY21 BUSINESS HIGHLIGHTS



## TRANSFORMED

Business operations to meet urgent global demand in healthcare for high quality respiratory protection solutions

## ACCELERATED

Customer adoption to increase installed base of healthcare product line in the major regions: North America, Asia and Europe

## EXPANDED

Global team of sales, product specialists and customer support by 80% in domestic and offshore markets

## ESTABLISHED

New state-of-the-art production facility in Sydney with expanded capacity up to revenue \$100M pa, shortened order lead times

## SCALED

Business model of lean manufacturing, modular design and low capex to deliver strong cashflow position

## OUTLOOK

There are clear signs the pandemic has shifted to a closing phase, which could impact 2H sales. Continued investment in growth will capitalise on our position that has now been successfully established in healthcare




# 1H FY21 OPERATIONAL UPDATE

# SIGNIFICANT GROWTH IN INSTALLED BASE

Global installed base grew 60% in the last 12 months and over 30% in the last 6 months to **95,000** units


- Installed device base continued to generate revenue from consumables and accessories in line with previous periods
- Consumables and accessories contribute 49% of total sales and have a higher average gross margin than the devices

Monthly Installed Base and Consumables Revenue %




# UPDATE ON SALES

REVENUE BY REGION 1H FY21



REVENUE BY INDUSTRY 1H FY21



## HEALTHCARE UPTAKE IN USA AND ASIA

Deployments to major hospitals: inc US Veteran Affairs (VA), University of Maryland and Parkview Health. Delivered accelerated penetration into healthcare (including ICUs, operating theatres and emergency). Entered new market geographies (ie Japan). Shifted market awareness - presented to US Association Perioperative Nursing AORN (600 attendees); Australian Society of Anaesthetists (200 attendees) and Asian Development Bank

## EUROPEAN & UK MARKETS

Work continued to push adoption in Europe and UK health markets. Expansion in Germany: Charite Berlin and deployments in NHS (Scotland and UK). Extended the distribution for healthcare and pharmaceutical

## CONSUMABLE/ACCESSORY SALES

Continued consumable and accessory sales (49%) in line with previous periods. Major driver healthcare uptake and product successfully being used

## INDUSTRIAL

Industrial sales positively impacted by the new production capacity shortening order lead times to underpin distributor confidence in supply chains. Extended lockdowns in northern hemisphere have created uncertainty and constrained business activity



# UPDATE ON PRODUCTION, SUPPLY CHAINS AND LOGISTICS



## New St Leonards facility

- Operational since early November 2020
- Current capacity of \$100m revenue per annum (1 shift, 5 days) with potential to ramp rapidly as required
- Minimum production disruption during set up and scale up
- Enables business to hold increased inventory levels and shorten lead times

## Artarmon facility

- Ongoing production as a contingency, with reduced activity
- As COVID-19 risks subside, the business plans are to consolidate to one location to capture increased efficiencies

## Supply Chains


- The business has experienced reliable inbound supply / logistics (in comparison to the first half of CY2020) while outbound cross-border freight remains slower than pre-COVID

## UPDATE ON PEOPLE

### EXPANDING SALES AND CUSTOMER SUPPORT TEAMS

▲ 80%

INCREASE IN SALES /  
CUSTOMER TEAMS



Hired 20 FTEs in key sales and technical roles to expand our customer teams in core and new markets

- Global with over 15 languages located in 12 countries
- Built-in capacity and skills for inside sales in response to COVID-19
- Continue to recruit and onboard

### NEW PRODUCT FOR SOURCE CONTROL

#### STERI-PLUS:

Exhalation valve filter (98% filtering efficiency)  
suitable for sterile environments or where  
source control is required

- First and only PAPR with Source Control
- NIOSH and CE Mark approved. TGA pending



# IMPACT OF COVID-19 ON 1H FY21 TRADING AND CURRENT MARKET CONDITIONS



Accelerated adoption in large markets  
Health, North America and Asia  
Scalable business model  
Unique competitive solution

## Impact of 1H FY21 and outlook

- Deployed into hundreds of hospitals (off a base of 20 a year ago), onboarded major reference clients (Sutter Health, Parkview) and observing CleanSpace referenced in healthcare PPE guidelines
  - Now there is a shift from reactive buying to strategic considered PPE purchasing. While CleanSpace is well positioned for this shift (offering cost advantages and high protection), this is expected to impact sales this half.
  - Uncertainty remains (new variants, ongoing outbreaks). There are clear signs the pandemic has shifted to a closing phase, and it is expected that 2H will be lower than 1H
- There has been a clear global step change in understanding the impact of respiratory outbreaks and the fundamental importance of protection. Along with ongoing outbreaks, it is expected that the world will be living with the implications of COVID-19 for a prolonged period
  - In this new phase, the business is well placed to accelerate growth in market share
    - Solid client base with demonstrated organisational wide application
    - Mainstream awareness and acceptance (written into PPE guidelines)
    - Expanded global sales capability and distribution channels
    - Significant opportunities in large healthcare markets
  - The business has considerable upside and remains positive on overall growth



# 1H FY21 FINANCIAL UPDATE

# REVENUE – 1H FY21

**\$39.7M**


SALES 1H FY21



**5x**

PCP 1H FY20

CleanSpace revenue (A\$m) and gross margin %




- Sales \$39.7m for first six months FY21. Continued growth from previous half year
- CY19 to CY20 actual growth of over 337% to \$60.8m; with year-on-year revenue growth since FY18
- Sales growth in both respirator and consumables/accessories
- Major driver for growth was healthcare markets (78% of revenue for 1H FY21) with industrial growth as well
- Gross margin for 1H FY21 78%, 10% up on PCP (68% 1H FY20) due to strong direct healthcare sales
- Gross margin will likely to be circa 73-75% post pandemic, reflective of changing healthcare/industrial sales mix

# EXPENSES – 1H FY21

## Highly Scalable Operating Model

CleanSpace pro forma operating expenses (A\$m) and as % of revenue (1H FY19 to 1H FY21)



- Cost base was leveraged with revenue growth to achieve strong EBITDA margins. Expense categories decreased as a % of revenue between 1H FY19 and 1H FY21
- As expected employee expenses were the business's largest expense category. Reflecting increased staff headcount in sales (all regions) and back office support
- Marketing and sales activity benefitted from inbound inquiries driven by COVID-19 pandemic that generated demand for respiratory protection
- Sales and marketing spend will increase to leverage recently entered markets and a larger installed base
- Increase in other operating expenses (inc administration and occupancy) reflect the growth in the business
- R&D and IP are in line with previous spend

# PRO FORMA INCOME STATEMENT – HALF YEAR

Pro forma 1H FY21 compared to Pro forma PCP and Pro forma prospectus forecast

A\$m	Pro forma actual		Pro forma forecast	1H FY21 variance (Actuals vs. Forecasts)	
	1H FY20	1H FY21	1H FY21F	Δ (A\$m)	Δ (%)
<b>Revenue</b>	7.3	39.7	31.8	7.9	24.9%
<b>Cost of sales</b>	(2.3)	(8.6)	(8.2)	(0.5)	5.9%
<b>Gross Profit</b>	5.0	31.1	23.6	7.4	31.5%
<b>Total Operating Expenses</b>	(6.9)	(11.0)	(12.0)	1.0	(8.3%)
<b>EBITDA</b>	(1.9)	20.1	11.6	8.5	72.6%
<b>Revenue Growth</b>	n/a	447%	338%		109%
<b>Gross Margin</b>	68%	78%	74%		4%
<b>EBITDA Margin</b>	(25%)	51%	37%		14%
<b>Respirators % of Revenue</b>	56%	51%	56%		(5%)
<b>Consumables, Accessories &amp; Other % of Revenue</b>	44%	49%	44%		5%


- EBITDA \$20.1m. Margin 51% (pro-forma)
- Strong cash conversion. Closing cash position of \$46.5m
- Revenue was in line with December 2020 trading update. Exceeded prospectus due to continued demand for Healthcare products, and no unscheduled production stoppages
- Gross margin was positively impacted by high proportion of healthcare, direct and accessory sales
- Consumables, accessories and other revenue was 49% of total revenue for half year
- Highly scalable operating base




# EBITDA AND CASH FLOW

Favourable cashflow model underpinned by low capex and working capital requirements

Pro forma EBITDA (\$ millions) and EBITDA margin (% of revenue)



Pro forma operating cash flows pre-financing and tax and free cash flow (\$ millions)



- Achieved operating cash flow conversion from EBITDA of approximately 100% in 1H FY21, highlighting the strong cash generation in the business model
- Expansion to the new facility in St Leonards went to plan, requiring minimal capital expenditure
- The business has invested in higher inventory levels to support increased sales and protect against potential supply chain disruptions
- Favourable cashflow model underpinned by low capex and working capital requirements

# SUMMARY BALANCE SHEET & CASH FLOWS

Summary Balance Sheet (A\$m)	as at 30-Jun-20	as at 30-Dec-20
Cash, cash equivalents and term deposits	10.3	46.5
Trade and other receivables	8.7	3.2
Inventories	1.8	4.8
Other current assets	0.2	0.4
Property, plant and equipment	0.9	1.7
Right-of-use assets	0.1	2.2
Other non-current assets	0.9	1.4
<b>Total assets</b>	<b>22.9</b>	<b>60.2</b>
Trade and other payables	4.3	4.0
Borrowings	4.7	2.4
Lease liabilities	0.1	2.2
Income tax liabilities	2.2	8.0
Employee benefits	0.5	0.7
Other liabilities	1.4	0.9
<b>Total liabilities</b>	<b>13.2</b>	<b>18.2</b>
<b>Net assets</b>	<b>9.7</b>	<b>42.0</b>

Summary Cash Flows (A\$m) - Statutory	1H FY20	2H FY20	1H FY21
Operating cash flows pre-financing and tax	(0.6)	5.5	20.1
Capital expenditure	(0.3)	(0.2)	(1.2)
<b>Free Cash Flow - Statutory</b>	<b>(0.9)</b>	<b>5.3</b>	<b>18.9</b>

- Strong balance sheet. Net Assets of \$42m
- Cash of \$46.5m – reflecting IPO and operating cashflow
- Inventories have increased to support sales and protect against supply chain disruptions
- Right of use assets and lease liabilities have increased as a result of new facility at St Leonards
- Trade receivables lower due to factory shut down over holiday period
- Borrowings decreased due to repayment to NSWHealth of \$2.3m 2015 Medical Device Fund loan (as scheduled)



## APPENDIX 1 – ADDITIONAL FINANCIAL INFORMATION

Hazards associated with WASTE WATER MANAGEMENT, such as sewage treatment plants, expose sewage treatment workers to airborne biological and chemical agents resulting in infectious disease or long term respiratory issues.

# PRO FORMA INCOME STATEMENT – FULL YEARS

Pro forma Historical Income Statements, Pro forma Forecast Income Statements, Pro forma Historical Annual and Forecast Annual Key Operating and Financial Metrics for FY18 to CY20

A\$m	Notes	Pro forma actual				Pro forma forecast		CY20 variance (Actuals vs. Forecasts)	
		FY18	FY19	CY19	FY20	CY20	CY20F	Δ (A\$m)	Δ (%)
<b>Revenue</b>		<b>7.8</b>	<b>11.2</b>	<b>13.9</b>	<b>28.4</b>	<b>60.8</b>	<b>52.9</b>	<b>7.9</b>	<b>15.0%</b>
Cost of Sales		(2.4)	(3.5)	(4.4)	(7.4)	(13.7)	(13.2)	(0.5)	3.6%
<b>Gross Profit</b>		<b>5.4</b>	<b>7.7</b>	<b>9.5</b>	<b>21.0</b>	<b>47.1</b>	<b>39.7</b>	<b>7.4</b>	<b>18.7%</b>
Other income	1	1.4	1.1	1.0	1.0	1.0	1.0	0.0	1.2%
Operating expenses		(9.2)	(11.1)	(12.5)	(15.8)	(20.0)	(21.1)	1.1	(4.8%)
<b>EBITDA</b>		<b>(2.4)</b>	<b>(2.3)</b>	<b>(2.0)</b>	<b>6.2</b>	<b>28.1</b>	<b>19.6</b>	<b>8.5</b>	<b>42.9%</b>
<i>Revenue growth</i>		<i>n/a</i>	<i>44%</i>	<i>n/a</i>	<i>153%</i>	<i>337%</i>	<i>280%</i>		<i>57%</i>
<i>Gross Profit Margin</i>		<i>70%</i>	<i>68%</i>	<i>68%</i>	<i>74%</i>	<i>78%</i>	<i>75%</i>		<i>3%</i>
<i>EBITDA Margin</i>		<i>(30%)</i>	<i>(21%)</i>	<i>(14%)</i>	<i>22%</i>	<i>46%</i>	<i>37%</i>		<i>9%</i>
<i>Respirator revenue %</i>		<i>58%</i>	<i>58%</i>	<i>57%</i>	<i>53%</i>	<i>51%</i>	<i>54%</i>		<i>(3%)</i>
<i>Consumables, Accessories &amp; Other revenue %</i>		<i>42%</i>	<i>42%</i>	<i>43%</i>	<i>47%</i>	<i>49%</i>	<i>46%</i>		<i>3%</i>

**Notes:**

1. Other income includes R&D Tax incentives, government grants and other sundry income.

# PRO FORMA INCOME STATEMENT

A\$m	Notes	FY18	FY19	FY20	CY19	CY20	1H FY19	2H FY19	1H FY20	2H FY20	1H FY21
<b>Revenue</b>		<b>7.8</b>	<b>11.2</b>	<b>28.4</b>	<b>13.9</b>	<b>60.8</b>	<b>4.6</b>	<b>6.7</b>	<b>7.3</b>	<b>21.1</b>	<b>39.7</b>
Cost of sales		(2.4)	(3.5)	(7.4)	(4.4)	(13.7)	(1.5)	(2.1)	(2.3)	(5.0)	(8.6)
<b>Gross Profit</b>		<b>5.4</b>	<b>7.7</b>	<b>21.0</b>	<b>9.5</b>	<b>47.1</b>	<b>3.1</b>	<b>4.6</b>	<b>4.9</b>	<b>16.1</b>	<b>31.1</b>
Other Income	1	1.4	1.1	1.0	1.0	1.0	0.1	1.0	0.0	1.0	0.0
Employee benefits expense		(3.6)	(4.7)	(8.5)	(5.9)	(11.0)	(2.2)	(2.5)	(3.4)	(5.2)	(5.8)
Marketing and sales expenses		(1.9)	(2.6)	(2.6)	(2.5)	(3.2)	(1.4)	(1.3)	(1.3)	(1.4)	(1.8)
R&D and IP expenses		(1.4)	(1.0)	(1.5)	(1.2)	(1.5)	(0.4)	(0.5)	(0.7)	(0.8)	(0.7)
Other operating expenses		(2.3)	(2.8)	(3.2)	(2.9)	(4.3)	(1.3)	(1.4)	(1.5)	(1.6)	(2.7)
<b>Total Operating Expenses</b>		<b>(9.2)</b>	<b>(11.1)</b>	<b>(15.8)</b>	<b>(12.6)</b>	<b>(20.0)</b>	<b>(5.3)</b>	<b>(5.8)</b>	<b>(6.8)</b>	<b>(9.0)</b>	<b>(11.0)</b>
<b>EBITDA</b>		<b>(2.4)</b>	<b>(2.3)</b>	<b>6.2</b>	<b>(2.0)</b>	<b>28.1</b>	<b>(2.2)</b>	<b>(0.2)</b>	<b>(1.8)</b>	<b>8.1</b>	<b>20.1</b>
Depreciation and amortisation		(0.3)	(0.4)	(0.5)	(0.4)	(1.0)	(0.2)	(0.2)	(0.2)	(0.3)	(0.7)
<b>EBIT</b>		<b>(2.7)</b>	<b>(2.7)</b>	<b>5.7</b>	<b>(2.4)</b>	<b>27.1</b>	<b>(2.3)</b>	<b>(0.3)</b>	<b>(2.1)</b>	<b>7.8</b>	<b>19.4</b>
Finance income/ (costs) net		(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	(0.0)
<b>Profit before tax</b>		<b>(2.7)</b>	<b>(2.7)</b>	<b>5.7</b>	<b>(2.4)</b>	<b>27.1</b>	<b>(2.3)</b>	<b>(0.4)</b>	<b>(2.1)</b>	<b>7.8</b>	<b>19.3</b>
Income Tax Expense		0.0	0.0	(0.9)	0.0	(6.5)	0.0	0.0	0.0	(0.9)	(5.6)
<b>NPAT</b>		<b>(2.7)</b>	<b>(2.7)</b>	<b>4.8</b>	<b>(2.4)</b>	<b>20.6</b>	<b>(2.3)</b>	<b>(0.4)</b>	<b>(2.1)</b>	<b>6.9</b>	<b>13.7</b>

**Notes:**

1. Other income includes R&D Tax incentives, government grants and other sundry income.

# 1H FY21 STATUTORY & PRO FORMA EBITDA RECONCILIATION

	A\$m
<b>Statutory 1H FY21 EBITDA</b>	<b>19.1</b>
IPO listing costs	1.2
Ongoing additional listing costs	(0.2)
<b>Pro forma 1H FY21 EBITDA</b>	<b>20.1</b>






## APPENDIX 2 – ABOUT CLEANSPACE

There are common activities where people are frequently exposed to contaminants in the workplace. In CONSTRUCTION, respirable crystalline silica is ubiquitous and deadly and the major cause of silicosis and COPD. And most notably silica is present in stonemasonry, grinding, and abrasive blasting.

# COMPANY HISTORY

CleanSpace has achieved regulatory approvals and opened and set-up key markets (domestic & export) to build a profitable global B2B business






# A CLEAR COMPETITIVE ADVANTAGE

A healthcare technology that provides high protection & lower cost; displacing both disposable masks and bulky PAPRs

## PROPRIETARY AIRSENSIT™ TECHNOLOGY



### OUR TECHNOLOGY

- Neck mounted compact design. Lightweight and small
- Breath responsive. Pressure sensors and algorithm continuously pressurise the mask though the breath
- Specialists in airflow control sampling, monitoring and adapting 100 Hz
- Micro-turbine toroidal motor: quiet, long wear, efficient), 26,000 rpm, high pressures and flows
- Lithium polymer smart battery technology: Light, long run time and fast re-charge

## CLEANSACE



- ✓ **High protection**
- ✓ **Lower cost**
- ✓ **Reduces heat stress**
- ✓ **Reusable**
- ✓ **No hoses or belts**
- ✓ **Light, small & easy to use**
- ✓ **Mobile & portable**
- ✓ **Fast disinfection time**

## TRADITIONAL RESPIRATOR OFFERINGS

### DISPOSABLES



- ✓ Light & simple
- ✗ Low protection
- ✗ Low compliance
- ✗ Moisture/CO2/heat problems
- ✗ Breathing resistance
- ✗ High disposable costs
- ✗ Stockpile & supply constraints







### TRADITIONAL PAPRS



- ✓ High Protection
- ✓ Reduces heat stress
- ✓ Reusable
- ✗ Heavy, bulky & complex
- ✗ Poor PPE compatibility
- ✗ High costs
- ✗ High inventory
- ✗ Slow to disinfect

# RESPIRATORY PROTECTION MARKET


CleanSpace operates across a broad range of regulated product categories

		Other: Dust Masks & Surgical Masks		NEGATIVE PRESSURE MASKS		POSITIVE PRESSURE MASKS	
		Disposables	Disposables	Air Purifying Respirator (APR)		Powered Air Purifying Respirator (PAPR)	Self Contained Breathing Apparatus (SCBA), Air Line
		Disposables	Disposables	Disposables	Half / Full Face	Full & Half Face	Full Face
							
Protection factor APF	No protection	No protection	10	10 (half) or 50 (Full)	25 (hood) or 1,000 (Half/Full)	1,000 to 10,000	
Typical sector	Retail	Healthcare	Healthcare / Industry	Industry	Industry	Industry	

# CLEANSPACE ADDRESSABLE MARKET US\$6.3BN

Global market opportunity across health and industry sectors

## RPE market size US\$4.7bn




Expected to grow 22% by 2024

*“The healthcare PPE industry has witnessed unprecedented global demand for its products during the COVID-19 pandemic. Government stockpiles in some countries quickly proved inadequate as healthcare facilities became overwhelmed with patients”.*

Frost & Sullivan, June 2020

## Regional RPE Market



Estimated addressable market \$6.3bn

Trends supporting the RPE market include:

- Heightened risk of respirator outbreaks
- Chronic respiratory disease burden
- Compliance and regulatory obligations
- Employer liabilities

# ESTABLISHED GLOBAL SALES NETWORK

Regional sales teams, distributors and partners established CleanSpace as a safety equipment provider with a multinational footprint

## DISTRIBUTION PARTNERS

- Industrial (100%) and in some healthcare markets (SE Asia and Europe)
- Purchasing arrangements with MROs, PPE and safety equipment specialists and sector specialists (i.e. in welding, lab and pharmaceutical)
- CleanSpace leverages its distributors network for their market reputation, sales teams and customer relationships to execute their product sales plan
- Ongoing strategy for expansion of the distribution network to cover new industry sectors and new geographies

## DIRECT SALES

- CleanSpace has set up direct sales models for healthcare in North America, Australia/NZ, UK and some countries in SE Asia
- Direct sales have a higher margin than sales to distributors



# GROWTH STRATEGY

CleanSpace continues to invest in new markets and product pipeline

IMMEDIATE OPPORTUNITY FOR ACCELERATED ADOPTION IN HEALTHCARE AS HIGH DEMAND THROUGH COVID19 DRIVES GLOBAL RESPIRATOR SALES AND AWARENESS

## CURRENT

- Continue momentum to grow installed base in health and industry
- Focused on core market geographies
- Expansion delivered by:
  - Existing products
  - Enhanced distribution & sales channels

## EXPAND INTO NEW MARKETS

- 'Standard of care' for respiratory protection in sophisticated high use sectors
- Investment in product pipeline and comprehensive solution-focused range
- Set up sales channels new geographic markets and industry sectors

## INNOVATE TO GROW NEW & EXISTING CUSTOMERS

- Service model underway
- Connectivity & data enabled
- Exploring acquisition opportunities



[WWW.CLEANSPACETECHNOLOGY.COM](http://WWW.CLEANSPACETECHNOLOGY.COM)